title: [Clinical investigation of 10 cases with acute renal failure induced by neuroleptics].
abstract: It is well known that the myoglobinuric acute renal failure caused by drugs is an important clinical aspect of nephrology. On the other hand, neuroleptic malignant syndrome is an uncommon, but potentially fatal, idiosyncratic reaction to neuroleptics and is characterized by muscular rigidity, fever, autonomic dysfunction and altered consciousness. The most common serious complication of malignant syndrome is rhabdomyolysis. We investigated 10 cases with acute renal failure induced by haloperidol and other neuroleptics. At the time they developed acute renal failure, the patients were taking a wide variety of medications. However, seven of the patients who developed acute renal failure, had received haloperidol, phenothiazine and anticholinaergic drugs, and 2 cases with acute renal failure were taking lithium. Characteristic clinical manifestations of malignant syndrome were observed in 7 patients who had been administered haloperidol orally or intravenously. All of the patients with acute renal failure induced by haloperidol, lithium and other neuroleptics were treated successfully with blood purification therapy (HD or HDF). We concluded that acute renal failure associated with malignant syndrome evoked by haloperidol is an indication for blood purification therapy.
authors.affiliation: First Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Soejima
authors.forename: M
authors.initials: M
authors.lastname: Suzuki
authors.forename: S
authors.initials: S
authors.lastname: Ishizuka
authors.forename: N
authors.initials: N
authors.lastname: Miyake
authors.forename: M
authors.initials: M
authors.lastname: Karube
authors.forename: K
authors.initials: K
authors.lastname: Fukuoka
authors.forename: S
authors.initials: S
authors.lastname: Minoshima
authors.forename: U
authors.initials: U
authors.lastname: Tanaka
authors.forename: Y
authors.initials: Y
authors.lastname: Arimura
authors.forename: K
authors.initials: K
authors.lastname: Nakabayasi
authors.forename: K
authors.initials: K
authors.lastname: Kitamoto
authors.forename: M
authors.initials: M
authors.lastname: Saitou
authors.forename: T
authors.initials: T
authors.lastname: Nagasawa
mesh_terms: D058186:Acute Kidney Injury / Q000139:chemically induced*; D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001463:Barbiturates / Q000009:adverse effects; D001569:Benzodiazepines / Q000009:adverse effects; D005260:Female; D006220:Haloperidol / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D010640:Phenothiazines / Q000009:adverse effects
chemical_list: D014150:Antipsychotic Agents; D001463:Barbiturates; D010640:Phenothiazines; D001569:Benzodiazepines; D006220:Haloperidol